CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAMPRNewsWire · 4 hr ago
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family ConferenceGlobeNewsWire · Sep 30, 2026
Bright Minds Biosciences to Present at Upcoming ConferencesGlobeNewsWire · Sep 4, 2026
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?Zacks Investment Research · Aug 27, 2026
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?Zacks Investment Research · Aug 26, 2026
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a BetZacks Investment Research · Aug 10, 2026Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 17, 2026 | -$1.39 | -$0.17 | Beat |
| May 20, 2026 | -$1.06 | -$0.80 | Beat |
| Feb 12, 2026 | -$0.98 | -$0.70 | Beat |
| Dec 23, 2025 | -$0.56 | -$0.41 | Beat |
| Aug 14, 2025 | -$0.59 | -$0.53 | Beat |
| May 15, 2025 | -$0.39 | -$0.29 | Beat |